(NASDAQ: RLYB) Rallybio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.06%.
Rallybio's earnings in 2026 is $45,551,000.On average, 4 Wall Street analysts forecast RLYB's earnings for 2026 to be -$24,938,634, with the lowest RLYB earnings forecast at -$28,769,097, and the highest RLYB earnings forecast at -$20,519,768. On average, 3 Wall Street analysts forecast RLYB's earnings for 2027 to be -$19,500,152, with the lowest RLYB earnings forecast at -$18,735,440, and the highest RLYB earnings forecast at -$20,073,686.
In 2028, RLYB is forecast to generate -$16,900,132 in earnings, with the lowest earnings forecast at -$16,237,382 and the highest earnings forecast at -$17,397,195.